Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome.
about
National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: Consensus Recommendations for Subsequent NeoplasmsPotential relationship between inadequate response to DNA damage and development of myelodysplastic syndrome.Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivorsSubsequent malignant neoplasms after hematopoietic cell transplantation.What is wrong with Fanconi anemia cells?Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia.Molecular characterisation of murine acute myeloid leukaemia induced by 56Fe ion and 137Cs gamma ray irradiation.The role of DNA damage repair in aging of adult stem cellsMyelodysplastic syndrome: an inability to appropriately respond to damaged DNA?Influence of DNA damage and repair upon the risk of treatment related leukemia.Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.Therapy-related myelodysplasia and acute myeloid leukemiaDNA damage and repair in human cancer: molecular mechanisms and contribution to therapy-related leukemias.Therapy-related myelodysplastic syndrome.Identifying DNA mutations in purified hematopoietic stem/progenitor cells.Therapy-related leukemia: clinical characteristics and analysis of new molecular risk factors in 96 adult patients.
P2860
Q29248394-C118C43F-ECED-493E-94B7-51E98E7F982DQ35016534-A4ABE3CB-33CF-4EEB-87E4-7036CF124480Q35327266-EF22BAB4-CC9F-41E7-8410-FA5926E795C7Q35678455-97A40E56-BBE5-4EA3-BA2D-EE9BC5047B1DQ36186819-B2C925BA-27D0-4B1C-A991-0C4E5DDD64F5Q36835902-77C8DD08-46ED-4439-8868-0D35F06EC11FQ37026983-1A7B72B4-F798-441E-A2C9-2E9AB20CE00CQ37045395-8528A79A-65F0-4081-99AC-9D37A48CA10AQ37060144-E27DE8C5-6A1C-4762-A07E-0E45170D9C2DQ37071688-20513976-6B27-4D23-A055-0E72F6F3AB60Q37144872-16A6D7C6-F420-4FE1-92CF-482E1E3A1886Q37402657-031F833F-4730-482F-83BF-5F3912E0FC27Q38052129-E7A96136-0ECF-483D-8602-4856CC0266DBQ38353167-5A312CD8-C644-4089-8BBF-5C80FAE92EB4Q42230854-B3B2F6A6-5EAD-4876-84C5-47258D5CE54AQ54642861-78E1E8D0-B1F1-4DB8-A87D-E2433627D301
P2860
Drug treatment in the development of mismatch repair defective acute leukemia and myelodysplastic syndrome.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Drug treatment in the developm ...... and myelodysplastic syndrome.
@ast
Drug treatment in the developm ...... and myelodysplastic syndrome.
@en
type
label
Drug treatment in the developm ...... and myelodysplastic syndrome.
@ast
Drug treatment in the developm ...... and myelodysplastic syndrome.
@en
prefLabel
Drug treatment in the developm ...... and myelodysplastic syndrome.
@ast
Drug treatment in the developm ...... and myelodysplastic syndrome.
@en
P2093
P50
P1433
P1476
Drug treatment in the developm ...... a and myelodysplastic syndrome
@en
P2093
Ida Casorelli
Livio Pagano
Margherita Bignami
Mariarosaria D'Errico
Peter Karran
Simona Sica
P304
P356
10.1016/S1568-7864(03)00020-X
P577
2003-05-01T00:00:00Z